Despite significant therapeutic advances, the prognosis of patients with heart failure (HF)
remains poor, and current therapeutic approaches are palliative in the sense that they do not …

This review summarizes the results of clinical trials of cell therapy in patients with heart
failure (HF). In contrast to acute myocardial infarction (where results have been consistently …

Cell therapy for patients with heart failure is still in its infancy. While early clinical studies
suggest that stem and progenitor cell transfer to the failing heart may be feasible, firm …

As the prevalence and incidence of ischemic heart disease continue to increase, so does
interest in ischemic heart failure management. Limitations of current therapies have led to …

Congestive heart failure remains a major public health problem and is frequently the end
result of cardiomyocyte apoptosis and fibrous replacement after myocardial infarction, a …

Heart failure (HF) is one of the leading causes of death worldwide and has reached
epidemic proportions in most industrialized nations. Despite major improvements in the …

Heart failure is the number one killer worldwide with~ 50% of patients dying within 5 years of
prognosis. The discovery of stem cells, which are capable of repairing the damaged portion …

Regenerating the human heart is a challenge that has engaged researchers and clinicians
around the globe for nearly a century. From the repair of the first septal defect in 1953 …

Heart failure is the leading cause of death worldwide, and current therapies only delay
progression of the disease. Laboratory experiments and recent clinical trials suggest that …

The development of cells for regenerative therapy has encountered many pitfalls on its path
to clinical translation. In cardiology, clinical studies of heart-targeted cell therapies began …